Aldosterone as an endogenous cardiovascular toxin and the options for its therapeutic management;Aldosteron jako endogenní kardiovaskulární toxin a možnosti jeho terapeutického ovlivnění

Vnitrni Lekarstvi

Volumn 57, Issue 12, 2011, Pages 1012-1016

  Horký, Karel ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Aldosterone; Aliskiren; Endogenous cardiovascular toxin; Extra renal effects of aldosterone; Hyperaldosteronism

Indexed keywords

ALDOSTERONE; ALISKIREN; CARDIOTOXIN; MINERALOCORTICOID RECEPTOR; NITRIC OXIDE;

ARTICLE; BLOOD CLOTTING; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; DIURESIS; ELECTROLYTE EXCRETION; ENDOTHELIAL DYSFUNCTION; ESSENTIAL HYPERTENSION; HEART FAILURE; HEART MUSCLE; HEART MUSCLE FIBROSIS; HIGH POTASSIUM INTAKE; HUMAN; KIDNEY; KIDNEY FUNCTION; MICROTHROMBUS; OXIDATIVE STRESS; PARACRINE SIGNALING; PATHOPHYSIOLOGY; PLEIOTROPY; PULSE WAVE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SALT INTAKE; THROMBOGENICITY; VASCULAR FIBROSIS;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR PHYSIOLOGICAL PHENOMENA; HUMANS;

EID: 84855605935     PISSN: 0042773X     EISSN: 18017592     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Vonend O, Quack I, Rump LC. Aldosterone und Hypertonie. Wien Klin Wochenshr 2010; 122: 65-74.
2. Gordon RD. Primary aldosteronism - actual epidemics or false alarm? Arq Bras Endocrinol Metab 2004; 48: 666-673.
3. Funder JW, Carey RM, Fardella C et al. Endocrine Society. Case detection, diagnosis and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrin Metab 2008; 9: 3266-3281.
4. Widimský jr. J. Primární hyperaldosteronizmus: epidemie anebo jen častá příčina sekundární hypertenze. Cor Vasa 2008; 50: 366-367.
5. Štrauch B, Zelinka T, Widimský jr. J et al. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens 2003; 17: 349-352. (Pubitemid 36625965)
6. Miliez P, Girard X, Plouinn PF et al. Evidence for an increased rate of cardiovascular events in patients with primary hyperaldosteronism. J Am J Coll Cardiol 2005; 45: 1243-1248.
7. Stehr CB, Mellado R, Ocaranza MP et al. Increase levels of oxidative stress, subclinical inflammation and myocardial fibrosis markers in primary aldosteronism patients. J Hypertens 2010; 28: 2120-2126.
8. Rossi GP, DiBello V, Ganzaroli C et al. Excess of adosterone is associated with alterations of myocardial textures in primary aldosteronism Hypertension 2002; 40: 523-526.
9. Pitt B, Zanand F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717. (Pubitemid 29407370)
10. Pitt B, Remme W, Zanand F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321. (Pubitemid 36384098)
11. Struthers AD, MacDonald TM. Review of aldosterone and angiotensin II-induced target organ damage and prevention. Cardiovasc Res 2004; 61: 663-670. (Pubitemid 38249465)
12. Chai W, Danser AH. Why are mineralocorticoid receptor antagonists cardioprotective? Naunyn-Schmiedbergs Arch Parmacol 2006; 374: 153-162. (Pubitemid 44819249)
13. Barbato JC, Rashid S, Mulrow PJ et al. Mechanisms for aldosterone and spirolactone-induced positive inotropic action in the rat heart. Hypertension 2004; 44: 751-757. (Pubitemid 39435249)
14. Funder JW. The nongenomic actions of aldosterone. Endocr Rev 2005; 26: 313-321. (Pubitemid 40686645)
15. Urabe A, Izumi T, Abe Y et al. Effects of eplerenone and salt intake on left ventricular remodeling after myocardial infarction in rats. Hypertens Res 2006; 29: 627-634. (Pubitemid 44430472)
16. Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 2007; 3: 486-492. (Pubitemid 47313030)
17. Krum H, Gilbert RE. Novel therapies blocking the renin-angiotensin- aldosterone system in the management of hypertension and related disorders. J Hypertens 2007; 25: 25-35. (Pubitemid 44885658)
18. Büssenmaker E, Hillebrand U, Hausberg K et al. Pathogenesis of hypertension: Interactions among sodium, potassium and aldosterone. Am J Kidney Dis 2010; 55: 1111-1123.
19. Tomaschitz A, Maerz W, Pilz S et al. Aldosterone/renin ratio determines peripheral and central blood pessure values over a broad range. J Am Coll Cardiol 2010; 55: 2171-2178.
20. Hillebrand U, Schillers H, Rietthmüller K et al. Dose-dependent endothelial cell growth and stiffening by aldosterone: endothelial protection by eplerenone. J Hypertens 2007; 25: 639-647. (Pubitemid 46213803)
21. Shah NC, Pringle S, Struthers A. Aldosterone blockade over and above ACE-Inhibitors in patients with coronary artery disease but without heart failure. J Renin Angiotensin Aldosterone Syst 2006; 7: 20-30. (Pubitemid 43891241)
22. Wray DW, Supiano MA. Impact of aldosterone receptor blockade compared with thiazide therapy on sympathetic nervous system function in geriatric hypertension. Hypertension 2010; 55: 1217-1223.
23. Anand K, Mooss AN, Mohiuddin SM. Aldosterone inhibition reduces the risk of sudden cardiac death in patients with heart failure. J Renin Angiotensin Aldosterone Syst 2006; 7: 15-19. (Pubitemid 43891240)
24. Ezekowitz JA, McAlister FS. Aldosterone blockade and left ventricular dysfunction: a systemic review of randomized clinical trials. Eur Heart J 2009; 30: 469-477.
25. Struthers AD. The clinical implications of aldosterone escape in congestive heart failure. Eur J Heart Fail 2004; 6: 539-545. (Pubitemid 39070505)
26. Struthers AD. Aldosterone blockade in cardiovascular disease. Heart 2004; 90: 1229-1234. (Pubitemid 39279920)